Home
Conditions
Breast Diseases

Clinical trial condition

Breast Diseases

Explore clinical trials studying Breast Diseases. Study availability and eligibility vary by location and protocol.

10,381 public trials 1,998 recruiting studies

Refine in advanced search Browse all conditions

Breast Diseases trial results

Completed

Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

NCT00513058

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations: Centre de Lutte Contre le Cancer Georges-Francois Leclerc Dijon, France

Centre Oscar Lambret Lille, France

Institut Curie Hopital Paris, France

Centre Rene Huguenin Saint-Cloud, France

View Trial Details

Completed

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

NCT01045304

Conditions: Breast Cancer, Metastatic, Breast Diseases, Breast Neoplasms, +8 more
Locations: Sanofi-Aventis Investigational Site Number 036002 Parkville, Australia

Sanofi-Aventis Investigational Site Number 036001 Perth, Australia

Sanofi-Aventis Investigational Site Number 036003 Westmead, Australia

Sanofi-Aventis Investigational Site Number 056001 Brussels, Belgium

View all 20 locations

View Trial Details

Completed

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

NCT00679341

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations: Not specified

View Trial Details

Completed

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

NCT00049452

Conditions: Bone Diseases, Bone Diseases, Metabolic, Breast Cancer, +10 more
Locations: Carl and Dorothy Bennett Cancer Center at Stamford Hospital Stamford, Connecticut, United States

Valley Hospital - Paramus Paramus, New Jersey, United States

Herbert Irving Comprehensive Cancer Center at Columbia University New York, United States

View Trial Details

Completed

An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer

NCT00425854

Conditions: Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
Locations: 1200.10.3201 Boehringer Ingelheim Investigational Site Brussels, Belgium

1200.10.3208 Boehringer Ingelheim Investigational Site Brussels, Belgium

1200.10.3203 Boehringer Ingelheim Investigational Site Charleroi, Belgium

1200.10.3205 Boehringer Ingelheim Investigational Site Ghent, Belgium

View all 14 locations

View Trial Details

Completed

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

NCT00826267

Conditions: Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
Locations: 1200.44.01001 Boehringer Ingelheim Investigational Site Houston, Texas, United States

1200.44.12008 Boehringer Ingelheim Investigational Site Brasília, Brazil

1200.44.12011 Boehringer Ingelheim Investigational Site Cachoeiro de Itapemirim, Brazil

1200.44.12012 Boehringer Ingelheim Investigational Site Campo Grande, Brazil

View all 17 locations

View Trial Details

Completed

Docetaxel in Breast Cancer

NCT00312208

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations: Sanofi-Aventis Bridgewater, New Jersey, United States

Sanofi-Aventis Buenos Aires, Argentina

Sanofi-Aventis Macquarie Park, Australia

Sanofi-Aventis Brussels, Belgium

View all 37 locations

View Trial Details

Completed

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

NCT00708214

Conditions: Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
Locations: 1200.5.3306A Boehringer Ingelheim Investigational Site Caen, France

1200.5.3304A Boehringer Ingelheim Investigational Site Nice, France

1200.5.3301A Boehringer Ingelheim Investigational Site Paris, France

1200.5.3305A Boehringer Ingelheim Investigational Site Paris, France

View Trial Details

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

NCT00875979

Conditions: Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +4 more
Locations: Boca Raton, Florida, United States

Deerfield Beach, Florida, United States

Maywood, Illinois, United States

Indianapolis, Indiana, United States

View all 20 locations

View Trial Details

Completed

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

NCT00121134

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations: University of California, San Francisco San Francisco, California, United States

Indiana University Cancer Center Indianapolis, Indiana, United States

Beth Israel Deaconess Medical Center Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Breast Diseases

Breast Diseases trial results

Related conditions